The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
36 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $18,961,164 in first-year total cost, median $499,897.
Most frequent study sections
- Special Emphasis Panel[ZRG1 AN-P (11)]15
- Special Emphasis Panel[ZRG1 NV-G (13)]4
- Special Emphasis Panel[ZRG1 NV-H (13)]4
- Special Emphasis Panel[ZAG1 ZIJ-2 (M2)]2
- Special Emphasis Panel[ZRG1 AN-P (10)]2
Most frequent institutions
- 3P BIOTECHNOLOGIES, INC.3
- AROMHA, INC.2
- CEIBA BIO INC.2
- NEUCYTE, INC.2
- 3D BIOANALYTIX, INC.1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2025 | Digital Accessible Remote Olfactory Mediated Health Assessments forPreclinical AD2R42AG062130-05 | REINEKE, SEAN | AROMHA, INC., MD | $1,249,670 | ZRG1 |
| 2025 | Development of a therapeutic nanobody targeting brain TNFa for the treatment of Alzheimer Disease2R42AG080864-02 | D'ADAMIO, LUCIANOTAGLIETTI, MARCO | NANONEWRON LLC, NJ | $979,592 | ZRG1 |
| 2025 | Development of "Imagnostix": A Liquid Biopsy System for Alzheimer's Disease2R42AG078718-02A1 | LI, YUANCHENGMAO, HUI | 5M BIOMED, LLC, GA | $888,723 | ZRG1 |
| 2025 | Mosaic Display of Multivalent Tau and A-Beta peptides on Immunogenic SNAP Liposomes2R42AG082620-03 | DAI, CHUNLINGHUANG, WEI-CHIAO | POP BIOTECHNOLOGIES, INC, NY | $833,334 | ZAG1 |
| 2025 | Trans Spinal Delivery of Targeted Exosomal Formulation of Curcuminoids to Treat AD1R41AG090217-01A1 | GUPTA, RAMESH C | 3P BIOTECHNOLOGIES, INC., KY | $506,434 | ZRG1 |
| 2025 | Development of Platelet-Derived Exercise Mimetics as a Treatment for Alzheimer's Disease and Alzhimer's Disease Related Dementias1R42AG097334-01 | DING, ZHAOQING | CEIBA BIO INC., CA | $506,198 | ZAG1 |
| 2025 | Scalable cGMP production of SV2A PET tracers using photoredox chemistry for applications in clinical trials and early AD diagnosis1R41AG097311-01 | CAI, ZHENGXIN | SYNVEST IMAGING INC., NC | $499,844 | ZAG1 |
| 2025 | Preclinical efficacy of an APOE targeted antibody for Alzheimer's disease1R41AG092063-01 | O'HARE, MICHAELYOU, JINSAM | EPOCH BIOTECH, LLC, MA | $498,709 | ZRG1 |
| 2025 | Digital Accessible Remote Olfactory Mediated Health Assessments for Lewy Body Disease1R41AG091992-01A1 | ALBERS, MARK WREINEKE, SEAN | AROMHA, INC., MD | $493,964 | ZRG1 |
| 2025 | An Eyedrop Diagnostic Test for Alzheimer's Disease1R42AG097309-01 | BENNETT, RACHEL ELISEDUBACH, JOHN | TAUVISION, INC., MA | $493,384 | ZAG1 |
| 2025 | Neurotrophic Drug Development for Alzheimer's Disease1R41AG094359-01 | SATHYANESAN, SAMUEL NEWTON | ENRECTEC LLC, SD | $475,014 | ZRG1 |
| 2025 | Commercial production of alpha-synuclein fibrils amplified from human postmortem brain tissue to expand the availability of a critical research tool for Parkinson's disease1R41NS145857-01 | KOTZBAUER, PAUL T | HELICAL BIOSCIENCES LLC, MO | $395,951 | ZNS1 |
| 2025 | VR-CARES: Feasibility of Virtual Reality for Caregiver Assembly, Relief, Empowerment, and Support to improve social connection, health, and at-home dementia care1R41AG092119-01 | BANDINI, JULIASTAMPS, JENNIFER JOY | RENDEVER, INC., MA | $349,333 | ZRG1 |
| 2025 | Targeting aVb8 integrin to restore astrocyte-microglia crosstalk to treat Alzheimer's disease1R41AG092194-01A1 | ARNOLD, THOMAS DARMODYBUTOVSKY, OLEGSHEPPARD, DEAN | GLIAL THERAPEUTICS, LLC, MA | $254,896 | ZRG1 |
| 2025 | Phase I STTR: Targeting substrate of gamma-secretase for selective amyloid reduction in Alzheimer’s Disease1R41AG092199-01 | WANG, CHUNYU | ALPHAMEMORY, LLC, NY | $252,124 | ZRG1 |
| 2025 | Novel AI-driven music-based intervention to reduce behavioral and psychological symptoms for people living with dementia1R41AG092161-01A1 | KOFFLER, RICHARDMCCREEDY, ELLEN M | RUBATO, INC., CA | $250,812 | ZRG1 |
| 2024 | Developing blood-based exercise mimetic as a treatment for Alzheimer's disease and related dementias1R41AG090238-01 | DING, ZHAOQING | CEIBA BIO INC., CA | $509,038 | ZRG1 |
| 2024 | Developing a blood fatty acid-based algorithm as an early predictor of cognitive decline and dementia: Applying machine learning to harmonized data from prospective cohort studies1R41AG085816-01 | HARRIS, BILL | OMEGAQUANT ANALYTICS, LLC, SD | $506,500 | ZRG1 |
| 2024 | Targeted Exosomal Delivery of siRNA Therapeutics for Neuroinflammatory Diseases1R41AG084384-01A1 | GUPTA, RAMESH CWALLEN, RENA MARGARET | 3P BIOTECHNOLOGIES, INC., KY | $506,451 | ZRG1 |
| 2024 | Development of orally bioavailable and blood-brain barrier penetrant, small molecule TAK1 inhibitors as a novel treatment for Alzheimer's Disease1R41AG090212-01 | SCARNEO, SCOTT | EYDIS BIO, INC., NC | $506,267 | ZRG1 |
| 2024 | NanoLuciferase-based AD/ADRD Microphysiological Systems Platform for High-throughput Screening1R41AG085831-01 | POON, WAYNE W | NEUCYTE, INC., CA | $500,000 | ZRG1 |
| 2024 | Multi-target Peptide Drug for Alzheimer's Disease1R41AG084429-01A1 | KASUS-JACOBI, ANNE | ALZARROK BIO LLC, OK | $500,000 | ZRG1 |
| 2024 | Trans Spinal Delivery of a Targeted Nanoformulation of Curcuminoids to Treat AD1R41AG085737-01 | GUPTA, RAMESH C | 3P BIOTECHNOLOGIES, INC., KY | $499,964 | ZRG1 |
| 2024 | Dementia IDEAs: An Evidence-based Intervention for Dysphagia to supportthe Unique Needs of AD/ADRD Care Partners1R41AG085909-01 | WERNER, NICOLE EZURAW, MATTHEW | BETTER BRAINS, INC, CA | $499,964 | ZRG1 |
| 2024 | Acetylated Tau Immunotherapy for Alzheimer's Disease1R41AG085770-01 | GAN, LISINHA, ANJANA | AETON THERAPEUTICS, INC., CA | $499,911 | ZRG1 |
| 2024 | Development of Small-Molecule Degraders of APP as the first-in-class drugs for Alzheimer's therapy1R41AG090241-01 | HAO, CHUNHAI CHARLIE | DEGROME THERAPEUTICS, INC., IN | $499,883 | ZRG1 |
| 2024 | Develop a novel strategy to deliver N-acetylcysteine for AD treatment1R41AG087769-01A1 | FAN, DAPINGXU, PEISHENG | ACEPRE, LLC, SC | $499,441 | ZRG1 |
| 2024 | Non-toxic CNS drug delivery across the BBB in Alzheimer's and other dementias1R41AG079748-01A1 | ROSENZWEIG, STEVEN ALAN | SOMATOCEUTICS, LLC, SC | $474,531 | ZRG1 |
| 2024 | High-Content Screen to Identify Small Molecule Therapeutics that Reduce Aberrant Lipid Accumulation in APOE4 Alzheimer's Disease1R41AG087802-01A1 | LAM, KELVIN T | MCM6 THERAPEUTICS, INC., MA | $473,216 | ZRG1 |
| 2024 | Development of a blood-based test for neurodegenerative diseases1R41AG087866-01 | PANKOW, SANDRAYATES III, JOHN R | 3D BIOANALYTIX, INC., CA | $472,695 | ZRG1 |
| 2024 | Development of a Growth Hormone Receptor antagonist for the delay or prevention of ADRD1R41AG085916-01 | BRODY, RICHARD SHUFFMAN, DEREK MAJORKOPCHICK, JOHN JOSEPHMILMAN, SOFIYA | MOLECULAR TECHNOLOGIES LABORATORIES LLC, OH | $275,070 | ZRG1 |
| 2023 | Phase 1 Trial to Assess Safety and Immune Effects of Xenon Gas in Healthy Human Subjects2R42AG073059-02 | ILIN, ILYAWEINER, HOWARD L | GENERAL BIOPHYSICS, LLC, MA | $1,318,445 | ZRG1 |
| 2023 | Miniaturized AD/ADRD Microphysiological Systems Platform for High-throughput Screening1R41AG084421-01 | POON, WAYNE W | NEUCYTE, INC., CA | $500,000 | ZRG1 |
| 2023 | Creating an sxRNA Organoid Product for Advancing the Study, Prevention and Treatment of Alzheimer's disease (AD) and Alzheimer's-disease-related dementias (ADRD)1R41AG081123-01A1 | PALUH, JANET LTENENBAUM, SCOTT | SXRNA TECHNOLOGIES, INC., NY | $500,000 | ZRG1 |
| 2023 | Developing a novel system combining cognitive assessment with PASCALL FDA-cleared intraoperative anesthesia EEG brain monitor to prevent postoperative neurocognitive disorders in aging patients1R42AG084399-01 | LE MAU, TUANPURDON, PATRICK L. | PASCALL SYSTEMS, INCORPORATED, MA | $299,893 | ZRG1 |
| 2023 | A Novel Technology to Disseminate WOOP (Wish, Outcome, Obstacle, Plan) to Dementia Caregivers1R41AG084405-01 | FEDUS, DONNA B | BORROW MY GLASSES, LLC, CT | $191,913 | ZRG1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.